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Abstract
Cognitive impairment occurs in both schizophrenia and diabetes. There is currently limited understanding whether
schizophrenia with diabetes has more serious cognitive deficits than schizophrenia without diabetes or diabetes only. This
study assessed cognitive performance in 190 healthy controls, 106 diabetes only, 127 schizophrenia without diabetes and
55 schizophrenia with diabetes. This study was conducted from January 2008 to December 2010. Compared to healthy
controls, all patient groups had significantly decreased total and five index RBANS scores (all p,0.01–p,0.001), except for
the visuospatial/constructional index. Schizophrenia with diabetes performed worse than schizophrenia without diabetes in
immediate memory (p,0.01) and total RBANS scores (,0.05), and showed a trend for decreased attention (p = 0.052) and
visuospatial/constructional capacity (p = 0.063). Schizophrenia with diabetes performed worse than diabetes only in
immediate memory (p,0.001) and attention (p,0.05), and showed a trend for decreased total RBANS scores (p = 0.069).
Regression analysis showed that the RBANS had modest correlations with schizophrenia’ PANSS scores, their duration of
current antipsychotic treatment, and diagnosis of diabetes. Schizophrenia with co-morbid diabetes showed more cognitive
impairment than schizophrenia without diabetes and diabetes only, especially in immediate memory and attention.
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Introduction
Cognitive deficits in schizophrenia have been well identified and
are important indices of functional and treatment outcomes in
patients [1,2,3]. Cognitive impairment in schizophrenia involves
multiple domains, such as memory, attention, perception and
processing speed [4,5,6]. Longitudinal studies have suggested that
many of these cognitive impairments are stable over time and may
persist after the remission of psychotic symptoms [7,8]. The
deficits in cognitive function can decrease the quality of life and
increase unemployment rates for patients with schizophrenia [9].
Diabetes is a complex endocrine disease with a series of
complications. Human and animal studies show that diabetes is
also associated with cognitive impairment [10,11,12]. Diabetes
related factors such as insulin resistance, hyperglycemia, hyper-
tension and lipid metabolic disorders may affect cognitive function
[13,14,15]. Moreover, studies have suggested that verbal memory
and processing speed are the cognitive domains which are usually
impaired in diabetes [16,17,18].
Diabetes has been reported to be about two to four times higher
in patients with schizophrenia than in the general population, and
it occurs in about 10–15% of patients with schizophrenia
[19,20,21]. As schizophrenia or diabetes alone has cognitive
vulnerability, the co-morbidity of both diseases may lead to an
increased rate and magnitude of cognitive deficits. However, the
contribution of diabetes to cognitive impairment in schizophrenia
has seldom been investigated. To our knowledge, only two studies
addressed this issue, with a preliminary result that schizophrenia
with diabetes was more cognitively impaired than schizophrenia
without diabetes [17,22]. Moreover, the severity of these cognitive
impairments was associated with the severity of diabetes in these
patients. The issue of cognitive impairments in the co-morbidity of
schizophrenia and diabetes deserves further investigation, since for
schizophrenia, the prevention and treatment of diabetes might
prove especially beneficial, yielding better cognitive outcomes and
improved general health [17].
This study proposes to address these areas and aims to test: (1)
whether cognitive impairments are different in schizophrenia with
and without diabetes and different from diabetes only compared to
healthy controls in the Chinese Han population; (2) whether
schizophrenia with diabetes have the worst cognitive impairment
among these tested groups; and (3) whether the schizophrenia with
diabetes group shows the worst metabolic disorders in comparison
to the other groups. We hypothesize that exacerbated cognitive
deficits will be present in schizophrenia patients with diabetes
relative to patients with either schizophrenia-only or diabetes-only.
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Materials and Methods
Ethics Statement
A complete description of the study was provided to all subjects
and they all provided their written informed consent to participate
in the study. The protocol of the study for all subjects was
approved by the Institutional Review Board, Beijing HuiLong-
Guan Hospital.
A psychiatrist evaluated all the participants to test whether they
had the capacity to content. The research procedure was
explained and it was ensured that all the research participants
understood what they were required to do in the study through a
detailed interview. This was aimed to maximise the understanding
of the subject by using appropriate language to the subject’s level
of comprehension and emotional readiness. If he/she was willing
to assent to participate in the research but was unable to
understand the complexity of the research processes, the research
was then described to the parent or guardian with the patients at
the same time. The parent and guardian would then explain the
research process to the participants using methods that with gauge
the subject’s interest and maximise their understanding. In these
situations, a written consent was provided by the parent or
guardian on behalf of the subject. If the participant did not agree
to participate in the research study, they were not discriminated
and were provided the same treatment as those that participated in
the study.
Subjects
A total of 182 patients with schizophrenia were recruited using a
cross-sectional naturalistic design at Beijing HuiLongGuan Hos-
pital, a Beijing City owned psychiatric hospital. The diagnoses for
each patient were made by two independent and experienced
psychiatrists and confirmed by the Structured Clinical Interview
for DSM-IV (SCID). All patients were aged between 25 and 70
years, had schizophrenia for at least 5 years, and were on stable
doses of oral antipsychotic drugs for at least 12 months prior to
entry into the study. Antipsychotic treatment consisted mainly of
monotherapy with clozapine (n = 82), risperidone (n = 45), and
other typical antipsychotics (n = 55), including haloperidol (n = 13),
chlorpromazine (n = 8), perphenazine (n = 13), sulpiride (n = 16)
and others (n = 5). The mean antipsychotic dose (as chlorprom-
azine equivalents) was 420.76270.2 mg/day. The average dura-
tion of the current antipsychotic treatment was 5.164.8 years at
the time of the investigation. All patients were of the chronic type,
with a mean illness course of 13.168.8 years. Patients were
hospitalized for an average of 10.069.5 years. Since admission, all
patients received dietetically balanced hospital meals, which were
occasionally supplemented by gifts (usually fruit), and patients had
the opportunity for about an hour of physical exercise every day.
One hundred and six (male/female = 65/41) outpatients with
type 2 diabetes mellitus (T2DM) were recruited from the
TangShan GongRen Hospital, a large general hospital located
in Tangshan city, about 80 km from Beijing. They were aged 25–
70 years (mean age: 54.168.0), with a mean duration of illness of
7.862.5 years (range 5–10). All the patients were receiving
conventional medical treatment. The most commonly prescribed
drugs were oral hypoglycemics such as Metformin and Repagli-
nide. No subjects used insulin. Patients with any history of
diagnosed cerebral vascular disease, coronary heart disease,
known neuropsychiatric or central nervous system diseases, or
any other complications such as nephropathy and retinopathy of
T2DM were excluded, since it is known that these cardio-
cerebrovascular and central nervous system diseases are associated
with cognitive impairments. Also, diabetic retinopathy and
nephropathy were strongly linked to impairment in the cognitive
domains [23,24]. In addition, none of the patients displayed
audiovisual or motor coordination impairment that would affect
the cognitive function tests.
One hundred and ninety normal controls (male/female = 113/
77) were recruited for the same period from the Beijing
community. The fasting glucose levels were measured at the start
of the study and again measured twice about one month later. Any
normal controls with fasting glucose .6.1 mmol/l at either of the
time points were excluded. Psychiatric disorders were ruled out
among the controls by a psychiatric interview conducted by a
psychiatrist.
Since the schizophrenia patients with diabetes were fairly old,
somehow due to the diabetes focus of this study, the samples of
controls and non-diabetic schizophrenia patients were specifically
recruited to match the ages of the diabetes samples. First, we
selected those schizophrenia patients with diabetes first, and then
we selected those schizophrenia patients without diabetes matched
for age, gender and education. Next, we recruited those
individuals with diabetes but without schizophrenia in a general
hospital based on the age, gender and education of the
schizophrenia patients with diabetes. At the same time, we
recruited the healthy controls without diabetes in the community
that matched gender, age and education for the diabetes only
group. Hence, these 4 groups were specially selected to be
comparable in demographic characteristics.
We obtained a complete medical history, physical examination
and laboratory tests from all subjects. All healthy controls were in
good physical health. All patients were free from other physical
diseases (other than T2DM), such as the central nervous system
diseases of stroke, tumors, Parkinson’s disease, Huntington’s
disease, seizure disorder, history of brain trauma and acute and
chronic infections. Neither patients nor control subjects suffered
from drug or alcohol abuse/dependence. Any subjects with a
diagnosis of dementia or mild cognitive impairment (MCI) were
excluded. Furthermore, all subjects were Han Chinese.
All subjects underwent fasting blood glucose testing using
standard procedures. Diabetes was diagnosed as persistent fasting
hyperglycemia ($126 mg/dL) or plasma glucose levels greater
than 200 mg/dL at 2 hours after a 75 g oral glucose load (2 h-
PG), which is consistent with the 1999 World Health Organization
diagnostic criteria for diabetes mellitus [25].
Clinical Assessment
Two psychiatrists who had more than five years of clinical
practice experience and who were blind to the clinical status and
treatment conditions assessed the patient’s psychopathology using
PANSS (Positive and negative syndrome scale) [26]. To ensure
consistent and reliable ratings, the two psychiatrists simultaneously
attended a training session for standardizing their use of the
PANSS prior to the start of the study. Thereafter, they maintained
an intra-class correlation coefficient of greater than 0.8 on the
PANSS at repeated assessments during the course of this study.
Cognitive Measures
The repeatable battery for the assessment of neuropsychological
status (RBANS) to measure cognitive function was individually
administered by trained investigators supervised by a research
psychiatrist. [27] The RBANS is composed of 12 subtests that are
used to calculate five age-adjusted index scores and a total score
[28]. Test indices are: immediate memory (composed of list
learning and story memory tasks); visuospatial/constructional
(composed of figure copy and line orientation tasks); language
(composed of picture naming and semantic fluency tasks);
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attention (composed of digit span and coding tasks); and delayed
memory (composed of list recall, story recall, figure recall and list
recognition tasks). Our group had previously translated RBANS
into Chinese and the clinical validity and its test-retest reliability
had been established among controls and schizophrenic patients
[29]. To ensure consistent and reliable ratings, the two clinical
psychologists simultaneously attended a training session for
standardizing their use of the RBANS prior to the start of the
study. Thereafter, they maintained an intra-class correlation
coefficient of 0.92 on the RBANS at repeated assessments during
the course of this study.
Blood Sampling
Venous blood from a forearm vein was collected from inpatients
between 7 and 9 am following an overnight fast. All fasting blood
glucose, cholesterol, triglyceride, high density lipoprotein and low
density lipoprotein products in the plasma were measured by a
technician, who was blind to the diagnostic status of subjects. The
identity of all subjects was indicated by a code number maintained
by the investigator until all biochemical analyses were completed.
Anthropometric Variables
The body weight and height were assessed in a standardized
fashion to calculate Body mass index (BMI). Height was measured
to the nearest millimetre, with the subjects barefooted and
standing upright. Body weight was measured with an electronic
scale calibrated to 60.1 kg, and subjects were weighed in light
indoor clothing. Waist circumference was measured with a
measuring tape at a level midway between the lower rib margin
and iliac crest with the tape in a horizontal position [30].
Statistical Analysis
Group comparisons on the demographic and clinical variables
used Chi squared or Fisher exact tests for the categorical variables
and Student t-tests or analysis of variance (ANOVA) for the
continuous variables. The RBANS were analysed using a 2x2
ANOVA representing the between factors of Diagnosis A
(schizophrenia vs no schizophrenia) and Diagnosis B (diabetes vs
no diabetes). For the RBANS comparisons, we also included age,
gender and education as covariates in the multivariate analyses of
covariance (MANCOVA). This was to examine significant
diagnosis differences across dependent measures from the RBANS
total score and its five cognitive domains, with the independent
predictors being Diagnosis A, Diagnosis B and Diagnosis A
multiplied by Diagnosis B interaction. Effect sizes (,0.1 = trivial
effect, 0.1–0.3= small effect, 0.3–0.5 = medium effect, .0.5 =
large difference effect). were also calculated for the two-way
comparisons and represented the mean difference, in standard
deviation units, between the groups of interest. In the post hoc
comparisons, a multiple testing correction has also been done.
Multiple regression models were used to quantify the amount of
variance in cognitive functioning explained by the psychopatho-
logical variables after controlling for several potential confounders,
such as gender, age, education and clinical variables. SPSS version
18.0 was used to perform all statistical analysis. Data were
presented as mean6SD. All p-values were two-tailed at the
significant level of ,0.05.
Results
Demographic and Clinical Information
Table 1 shows no significant differences among these four
examined groups in age, education and gender. Schizophrenia
with diabetes had the largest waist circumference. Moreover,
schizophrenia with diabetes showed higher fasting glucose and
triglyceride levels than schizophrenia without diabetes (both
p,0.05). Compared to healthy controls, diabetes only had larger
waist circumferences and fasting glucose (p,0.01). In addition,
diabetes only had higher fasting glucose, triglyceride and
cholesterol levels than schizophrenia with and without diabetes
(p,0.001). However, there were no significant differences in
height, hip, weight, BMI, high density lipoprotein or low density
lipoprotein among four groups (all p.0.05).
In addition, there were no significant differences between
schizophrenia with and without diabetes in any PANSS scores,
duration of illness, antipsychotic types, antipsychotic dose,
duration of current antipsychotic treatment and anti-Parkinsonian
drug treatment (all p.0.05) (Table 2).
Cognitive performance in schizophrenia with and
without diabetes, non-schizophrenia with diabetes and
healthy controls
The total and five index RBANS scores for all subjects are
summarized in Table 3. After controlling for age, education and
gender, the multivariate analysis of covariance (ANCOVA)
revealed statistically significant differences between schizophrenia
and no schizophrenia for all cognitive domains (F1,410 = 123.5,
p,0.001). Furthermore, Diagnosis A (schizophrenia vs no
schizophrenia) differences were significant for total RBANS scores
and all indices (all p,0.01–p,0.001), except for the visuospatial/
constructional index (p.0.05). Diagnosis B (diabetes vs no
diabetes) had significant effects on total cognitive test scores and
all indices (all p,0.05–p,0.001), except for the visuospatial/
constructional index (p.0.05). It was also found that there were
significant diagnosis A6diagnosis B effects on language (p,0.01)
and delayed memory (p,0.05).
In order to decompose these two-way interactions, we
compared the total and five index RBANS scores separately by
healthy controls, non-schizophrenia with diabetes and schizophre-
nia with and without diabetes. Compared to healthy controls, non-
schizophrenia with diabetes had worse cognitive performance in
the immediate memory, language, attention and delayed memory
(all p,0.01–p,0.001), with effect sizes ranging from 0.20–0.54.
Schizophrenia with and without diabetes had worse cognitive
performance in the total RBANS scores and all indices (all
p,0.001), with effect sizes ranging from 0.23–0.56, except for the
visuospatial/constructional index. Schizophrenia with diabetes
performed worse than non-schizophrenia with diabetes in
immediate memory (p,0.001) and attention (p,0.05), and they
showed a trend to decreases in total RBANS scores (p = 0.069),
with effect sizes ranging from 0.32–0.54. Schizophrenia with
diabetes performed worse than schizophrenia without diabetes in
immediate memory (p,0.01) and total RBANS scores (,0.05).
They also showed a trend to decreases in attention (p= 0.052) and
visuospatial/constructional functioning (p= 0.063), with effect
sizes ranging from 0.37–0.45. After controlling the gender, age,
education and clinical variables including duration of illness, age of
onset, antipsychotic treatment (atypical vs typical, dose and
duration of treatment), and hospitalization, anticholinergic drugs,
as well as PANSS, both the immediate memory and overall
RBANS remained significant (both p,0.05).
Associations of cognitive impairment with clinical
variables in schizophrenic patients
Since we found more significant cognitive impairment in
schizophrenia compared with healthy controls, the associations
of cognitive impairment with clinical psychopathological variables
Diabetes and Cognitive Deficits in Schizophrenia
PLOS ONE | www.plosone.org 3 June 2013 | Volume 8 | Issue 6 | e66299
were examined in schizophrenic patients. Using multivariate
regression analysis the following variables were independently
associated with the RBANS total scores: age (beta =20.43,
t =25.48, p,0.001); diabetes (beta =20.18, t =22.37, p,0.05);
education (beta = 0.18, t = 2.34, p,0.05); PANSS positive symp-
tom score (beta = 0.17, t = 2.18, p,0.05); and PANSS negative
symptom score (beta =20.17, t =22.16, p,0.05). These factors
together predicted 25.6% of the variance of the RBANS total
scores.
Data for the schizophrenia with or without diabetes were
analysed separately to assess the association of clinical character-
istics with cognitive impairment. In schizophrenia without
diabetes, multivariate regression analyses showed that the follow-
ing variables were independently associated with the RBANS total
score: age (beta =20.50, t =26.0, p,0.001); education (be-
ta = 0.22, t = 2.75, p,0.01); PANSS positive symptom score
(beta = 0.22, t = 2.0, p,0.05); and PANSS negative symptom
score (beta =20.20, t =22.51, p,0.05). In schizophrenia with
diabetes, the RBANS total score showed no multivariate
associations. However, the RBANS language score was associated
with: education (beta = 0.50, t = 3.70, p,0.001); PANSS general
symptom score (beta = 0.33, t = 2.41, p,0.05); and cholesterol
(beta =20.30, t =22.23, p,0.05).
Table 1. Demographic and clinical information of healthy controls, diabetes only, schizophrenia with and without diabetes.
No schizophrenia Schizophrenia
Healthy controls Diabetes only Schizophrenia without diabetes
Schizophrenia with
diabetes
Sample size 190 106 127 55
Sex, male 59.50% 61.10% 64.60% 61.80%
Age (years) 53.167.4 54.168.0 53.368.3 54.468.1
Education (years) 9.763.0 9.563.4 9.762.4 9.862.5
Height (cm) 166.167.6 167.467.9 167.267.0 167.066.8
Waist (cm) 88.0610.3 93.769.8* 92.3614.7 104.8610.1*+
Hip (cm) 98.067.2 100.968.5 102.8610.0 101.468.5
Weight (kg) 71.3613.5 72.4611.2 69.5613.8 78.5619.8
BMI (kg/m2) 25.763.9 25.863.3 24.964.4 28.066.3
Fast glucose (mmol/l) 5.161.4 9.063.2* 5.260.5++ 6.261.6++#
Cholesterol (mmol/l) NA 6.362.3 4.760.9++ 4.761.0++
Triglyceride (mmol/l) NA 6.066.0 1.660.8++ 2.461.4++#
High density lipoprotein (mmol/l) NA 1.260.3 1.460.6 1.360.2
Low density lipoprotein (mmol/l) NA 2.760.9 2.960.6 2.960.5
Mean6SD.
*indicates the comparison between healthy controls and schizophrenia with diabetes or diabetes only:
*p,0.01.
+indicates the comparison between diabetes only and schizophrenia with or without diabetes:
+p,0.05,
++p,0.001.
#indicates the comparison between schizophrenia with and without diabetes:
#p,0.01. NA= not applicable.
doi:10.1371/journal.pone.0066299.t001
Table 2. Characteristics of schizophrenia with and without diabetes.
Schizophrenia without
diabetes Schizophrenia with diabetes t or x2 p-value
Duration of illness (years) 13.467.5 11.669.3 20.32 0.750
Antipsychotic types (typicals/atypicals) 21/106 16/39 0.13 0.910
Antipsychotic dose (CPZ equivalents) 440.96304.1 385.76257.1 21.18 0.238
Duration of current antipsychotic treatment (months) 64.2656.3 60.4649.3 20.68 0.499
Anti-Parkinsonian drug (yes/no) 38/89 16/39 3.74 0.053
Score on positive symptom scale 13.165.8 12.366.0 20.79 0.428
Score on negative symptom scale 19.966.6 20.867.6 0.83 0.408
Score general psychopathology scale 25.966.3 26.166.2 0.23 0.820
Total PANSS score 58.8615.2 59.2615.0 0.18 0.854
Note: Mean6SD. CPZ = chlorpromazine; PANSS= Positive and negative syndrome scale.
doi:10.1371/journal.pone.0066299.t002
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Discussion
This study examined cognitive function in healthy controls,
schizophrenia with and without diabetes and diabetes only. In
general, compared to healthy controls, all three patient groups
displayed significant cognitive impairments. More specifically,
schizophrenia with diabetes had worse cognitive functioning than
schizophrenia without diabetes and diabetes only. Moreover, we
found increased triglyceride levels and waist circumferences that
provided significant indication of susceptibility of diabetes for
schizophrenia.
In this study, we found more significant cognitive impairments
in schizophrenia than in healthy controls across all cognitive
domains, except visuospatial/construction. These results are
consistent with our previous study [31], and are also supported
by other studies [1,4]. Studies have shown that the cognitive
impairment in schizophrenia may be associated with abnormalities
of brain structure, volume, neurotransmitter receptors, neuronal
development and genetic mutations [32,33,34,35,36]. However,
the pathophysiological mechanisms of cognitive impairments in
schizophrenia are not completely understood, and deserve further
investigation.
Our study indicated that cognitive impairments in diabetes only
were present in immediate memory, language, attention and
delayed memory. This is consistent with other studies [37,38].
Neuropathology and functional neuroimaging studies suggest that
cognitive impairments in diabetes may be caused by global and
regional dysfunctions of brain energetic metabolism, especially in
the hippocampal regions [39,40,41]. Studies have shown that
chronic hyperglycemia may cause a significant loss of cortical
neurons and reduce the neocortical capillary network, which is
associated with cognitive deficits in diabetes [42]. Moreover,
neuronal glucose malnutrition could cause excessive neuronal
pruning in the brain, resulting in cognitive impairment [43]. In
addition, hyperinsulinemia may inhibit synaptic activity and affect
cognitive functioning [44]. Taken together, these studies suggest
that diabetes may cause significant cognitive deficits.
Importantly, this study found that schizophrenia with diabetes
had more serious cognitive deficits than schizophrenia without
diabetes and diabetes only, mainly in immediate memory and
attention. These results are consistent with a previous study which
found worse cognitive performance across almost all aspects of
cognition in schizophrenia with diabetes compared to schizophre-
nia without diabetes and diabetes only [17]. Currently, the
discrepancies between Dickinson and our current study are still
not clear. Some factors, such as ethnic difference, genetic
background, experiment design and duration of disease may
contribute to these discrepancies. Taken together, these results
suggest that diabetes and schizophrenia may have additive effects
on cognitive deficits, especially on immediate memory and
attention.
A previous study showed that the neural underpinnings of
memory, which are among the most consistent and severe
neuropsychological deficits in schizophrenia, are associated with
hippocampal activation [45]. Abnormalities in the hippocampal
brain region may contribute to changes in learning and memory
[46,47]. Moreover, abnormalities in hippocampal structure and
function, which are critically involved in cognitive impairments in
learning and memory, are evident across multiple domains among
schizophrenia, including brain volume [46,48]. Furthermore,
animal studies have shown that diabetes impairs hippocampus-
dependent memory by reducing dendritic spine density, impairing
synaptic plasticity and reducing neurogenesis in the hippocampus
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impaired glucose regulation contributes to hippocampal damage
and to impaired memory [49]. Interestingly, these memory deficits
in schizophrenia may reflect deficiencies in glucose regulation, as a
few studies have shown that glucose administration improves these
deficits. Other studies have reported increases in verbal declarative
memory performance following glucose administration in double-
blind crossover designs [50,51]. These studies, together with our
finding of impaired immediate memory in schizophrenia with
diabetes, support the hypothesis that impaired glucose regulation/
availability contributes to the vulnerability for memory deficits in
schizophrenia, which may be associated with the extensive
hippocampal abnormalities in schizophrenia.
In addition, our results showed that the interaction effects of
both diagnoses on language and delayed memory were significant,
suggesting that both schizophrenia and diabetes could impair the
function of language and delayed memory, and produce the
synergistic (multiplicative) effects on these cognitive indices.
It is worthy of mentioning that schizophrenia patients without
diabetes had a higher ratio of patients who received atypical
antipsychotic agents than schizophrenia patients with diabetes in
our study. After controlling for the clinical variables including
antipsychotic treatment (atypical vs typical, dose and duration of
treatment), however, both the immediate memory and overall
RBANS remained significant (both p,0.05), suggesting that the
better performance in the schizophrenia without diabetes is not
due to the more atypical antipsychotic drugs. However, the
association between cognitive deficits and antipsychotic treatment
in schizophrenia is disputable. For example, a previous study
indicated that both typical and atypical antipsychotics did not have
a major effect on cognitive deficits in chronic patients with
schizophrenia [52]. However, other studies supported that atypical
antipsychotic drugs were associated with statistically significant but
small improvement in neurocognitive functioning in schizophrenia
[53,54]. Hence, this issue warrants more investigation using the
longitudinal study.
Several limitations of this study should be noted. First, we did
not measure the levels of glycosylated hemoglobin, which can
indicate the degree of control for blood glucose in the recent two to
three months [37]. Therefore, we could not confirm whether
schizophrenia with diabetes had worse blood glucose control than
diabetes only. Second, all patients with schizophrenia in this study
were of the chronic type. We could not distinguish whether the
diabetes in schizophrenia was caused by antipsychotic treatments
or whether it occurred before the antipsychotic treatments. Third,
we did not measure the levels of metabolite biomarkers, such as
cholesterol, triglyceride, and lipoprotein in healthy controls, and
thus we could not compare the healthy controls with the other
groups. Fourth, we found that schizophrenia patients with diabetes
had poorer cognitive function than the patients with diabetes but
without schizophrenia. However, the schizophrenia patients had
been hospitalized for an average of 10 years in this study. Although
we did not find that there was an association between the duration
of illness or hospitalization and hospitalization, it remains unclear
whether long-term institutionalization may have worsened cogni-
tion function of the mentally ill patients, which warrants further
investigation using a longitudinal design. Fifth, the samples were
fairly old, averaging 53 or 54 years of age, with an upper age limit
of 70 years. This related somehow to the diabetes focus of this
study. Since the samples of controls and non-diabetic schizophre-
nia patients were specifically recruited to match the ages of the
diabetes samples, the findings derived from such samples may not
fully generalize to younger groups. Moreover, age effects,
especially in the above-55 portion of each sample may confound
findings somewhat. Sixth, it is noteworthy that mean age minus
mean duration of illness yields an illness onset age averaging
around 40 years for our schizophrenia patients. According to our
previous study [55], the average onset age of the schizophrenia is
around 25 years. Hence, these are not ‘typical’ schizophrenia case,
probably due to the selected schizophrenia patients comorbid with
diabetes, and the results will not be generalized to other
schizophrenia samples. Seventh, it should be noted that our
RBANS total score in normal controls in this study was nearly one
standard deviation lower than the American normative data [56].
However, these results were consistent with other studies in China
[29,57], suggest that the lower RBANS total and index scores in
normal population in China than in Western countries may be due
to the differential education levels and cultural background.
However, further research will be needed to produce normative
values in Chinese population.
In summary, cognitive performance is significantly impaired in
both schizophrenia and diabetes. Schizophrenia with co-morbid
diabetes display increased cognitive impairment than both
schizophrenia without diabetes and diabetes only, especially in
immediate memory and attention, suggesting an additive effect of
schizophrenia and diabetes on cognitive deficits. However, due to
the nature of the cross-sectional design in our study, we cannot
provide a reasonable explanation for this additive effect, although
the synergism may be associated with the extensive hippocampal
abnormalities caused by the abnormal glucose metabolism.
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